By treating PARGi-treated ARH3 KO cells with genotoxins that target different DNA repair pathways, we observed a significant increase in the cancer cells’ vulnerability to the alkylating agents MMS and TMZ, thus supporting the role of PARP1 and PARP2 in repairing DNA damage caused by alkylating agents. The gene discussed is ADPRS; the disease is cancer.